COVID-19, Pulmonary Tuberculosis
Conditions
Brief summary
This is a randomized, double-blind, parallel-controlled study, for evaluation of safety and immunogenicity of three doses of an inactivated COVID-19 vaccine (CoronaVac) in pulmonary tuberculosis patients aged 18-75 years. 200 tuberculosis patients and 40 healthy adults aged 18-75 years will be recruited in this study. Of them, 200 pulmonary tuberculosis patients will be randomized at a 1:1 ratio to receive two doses of standard dosage CoronaVac plus one dose of double dosage CoronaVac or two doses of standard dosage CoronaVac plus one dose of standard dosage CoronaVac at a schedule of 0, 28, 56 days, respectively. Other 40 healthy subjects served as an external control group will be vaccinated with two doses of standard dosage CoronaVac at a schedule of 0, 28 days. The occurrence of adverse events within 28 days after each dose vaccination and serious adverse events within 3 months after full vaccination will be observed. In addition, blood samples will be collected on day 0 before the first dose and 28 days and 3 months after the last dose vaccination in all participants and 28 days after second dose in pulmonary tuberculosis patients. Each subject will remain in this study for 5 months (healthy group) or 6 months (tuberculosis group).
Interventions
BIOLOGICALStandard dosage inactivated vaccine
This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
BIOLOGICALDouble dosage inactivated vaccine
This vaccine contains 1200 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research & Development Co., Ltd. 0.5 ml / bottle.
Sponsors
Jiangsu Province Centers for Disease Control and Prevention
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Participants and investigators will be kept blinded.
Intervention model description
Pulmonary tuberculosis patients will be randomized at a 1:1 ratio to receive two doses of standard dosage CoronaVac plus one dose of double dosage CoronaVac or two doses of standard dosage CoronaVac plus one dose of standard dosage CoronaVac at a schedule of 0, 28, 56 days, respectively. Healthy subjects served as an external control group will be vaccinated with two doses of standard dosage CoronaVac at a schedule of 0, 28 days.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
for pulmonary tuberculosis patients: 1. Pulmonary tuberculosis patients aged 18-75 years who have not received COVID-19 vaccine. 2. The condition is determined to be stable by the clinician. 3. The subjects can provide with informed consent and sign informed consent form (ICF). 4. The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the follow-up of the study. 5. Axillary temperature ≤ 37.0℃. Inclusion criteria for healthy participants: 1.Healthy subjects aged 18-75 years who have not received COVID-19 vaccine. 2.The subjects can provide with informed consent and sign informed consent form (ICF). 3.The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the follow-up of the study. 4.Axillary temperature ≤ 37.0℃.
Exclusion criteria
for the first vaccination 1. Medical history or family history of convulsion, epilepsy, encephalopathy and psychosis. 2. HIV positive. 3. Cancer patients under treatment. 4. Allergic to any component of the research vaccines, or a history of hypersensitivity or serious reactions to vaccination. 5. Women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan in this study. 6. Severe chronic diseases or condition in progress cannot be controlled.( Grade 3 or higher as defined in the guidelines for the classification of adverse events in clinical trials for prophylactic vaccines). 7. Transaminase ≥ 3 times ULN or total bilirubin ≥2 times ULN, or other serious adverse reactions as determined by the clinician for antituberculosis treatment. 8. Congenital or acquired angioedema / neuroedema. 9. Asplenia or functional asplenia. 10. Thrombocytopenia or other clotting disorder (this may contraindicate intramuscular injection). 11. Immunosuppressant therapy, antiallergic therapy, cytotoxic therapy, high dose inhaled corticosteroid over the past 6 months (excluding corticosteroid spray for allergic rhinitis, surface corticosteroid for acute non-complicated dermatitis, and corticosteroid with dose less than 20mg/ day) 12. Received blood products within 4 months before vaccination. 13. Received other investigational drugs within 1 month prior to receiving the investigational vaccines. 14. Received other live attenuated vaccines within 1 month prior to receiving the investigational vaccines. 15. Received subunit or inactivated vaccine within 14 days prior to receiving investigational vaccine. 16. Any medical, psychological, social or other conditions that, in the investigator's judgment, are inconsistent with the study protocol or affect the subjects' informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| GMT of neutralizing antibodies against live SARS-CoV-2 virus on day 28 after the second dose. | On day 28 after the second dose | GMT of neutralizing antibodies against live SARS-CoV-2 virus on day 28 after the second dose. |
| Incidence of adverse reaction within 28 days after each dose | within 28 days after each dose | Incidence of adverse reaction within 28 days after each dose. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events within 28 days after each dose. | within 28 days after each dose | Incidence of adverse events within 28 days after each dose. |
| Incidence of unsolicited adverse events within 28 days after each dose. | within 28 days after each dose | Incidence of unsolicited adverse events within 28 days after each dose. |
| Incidence of serious adverse events (SAE) till the 3 months after the last vaccination. | within 3 months after the last vaccination | Incidence of serious adverse events (SAE) till the 3 months after the last vaccination. |
| Fold increase of anti-S protein of SARS-CoV-2 binding antibodies on day 28 and month 3 after the last dose in all groups and day 28 after second dose in pulmonary tuberculosis patients. | on day 28 and month 3 after the last dose in all groups and day 28 after second dose in pulmonary tuberculosis patients | Fold increase of anti-S protein of SARS-CoV-2 binding antibodies on day 28 and month 3 after the last dose in all groups and day 28 after second dose in pulmonary tuberculosis patients. |
| GMT of neutralizing antibodies against live SARS-CoV-2 virus on day 28 and month 3 after the last dose in pulmonary tuberculosis patients. | on day 28 and month 3 after the last dose in pulmonary tuberculosis patients | GMT of neutralizing antibodies against live SARS-CoV-2 virus on day 28 and month 3 after the last dose in pulmonary tuberculosis patients. |
| 8. Fold increase of neutralizing antibodies against live SARS-CoV-2 virus on day 28 and month 3 after the last dose in all groups and day 28 after second dose in pulmonary tuberculosis patients. | on day 28 and month 3 after the last dose in all groups and day 28 after second dose in pulmonary tuberculosis patients | Fold increase of neutralizing antibodies against live SARS-CoV-2 virus on day 28 and month 3 after the last dose in all groups and day 28 after second dose in pulmonary tuberculosis patients. |
| GMT of anti-S protein of SARS-CoV-2 binding antibodies on day 28 and month 3 after the last dose in all groups and day 28 after second dose in pulmonary tuberculosis patients. | on day 28 and month 3 after the last dose in all groups and day 28 after second dose in pulmonary tuberculosis patients | GMT of anti-S protein of SARS-CoV-2 binding antibodies measured by ELISA on day 28 and month 3 after the last dose in all groups and day 28 after second dose in tuberculosis patients. |
| Incidence of solicited adverse events within 7 days after each dose. | within 7 days after each dose | Incidence of solicited adverse events within 7 days after each dose. |
Other
| Measure | Time frame | Description |
|---|---|---|
| GMT of neutralizing antibodies against SARS-CoV-2 variants on day 28 and month 3 after the last dose in all groups and day 28 after second dose in pulmonary tuberculosis patients. | on day 28 and month 3 after the last dose in all groups and day 28 after second dose in pulmonary tuberculosis patients | GMT of neutralizing antibodies against SARS-CoV-2 variants on day 28 and month 3 after the last dose in all groups and day 28 after second dose in pulmonary tuberculosis patients. |
Countries
China
Contacts
Primary ContactJing-Xin Li, PhD
Outcome results
None listed